April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Inhibition of Corneal Neovascularization: Comparison of Different Doses of Bevacizumab Versus Dexamethasone in an Experimental Rat Model
Author Affiliations & Notes
  • J. G. Conrath
    Ophthalmology, Hopital de la Timone, Marseille, France
  • F. Matonti
    Ophthalmology, Hopital de la Timone, Marseille, France
  • B. Ridings
    Ophthalmology, Hopital de la Timone, Marseille, France
  • F. Chavane
    INCM, CNRS UMR 6193/Marseille, France
  • G. S. Masson
    INCM, CNRS UMR 6193/Marseille, France
  • L. Hoffart
    Ophthalmology, Hopital de la Timone, Marseille, France
  • Footnotes
    Commercial Relationships  J.G. Conrath, None; F. Matonti, None; B. Ridings, None; F. Chavane, None; G.S. Masson, None; L. Hoffart, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4969. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. G. Conrath, F. Matonti, B. Ridings, F. Chavane, G. S. Masson, L. Hoffart; Inhibition of Corneal Neovascularization: Comparison of Different Doses of Bevacizumab Versus Dexamethasone in an Experimental Rat Model. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4969.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To compare the inhibitory effects of different doses of bevacizumab with both saline and dexamethasone on the inflammatory angiogenesis in the rat cornea induced by small chemical lesions.

Methods: : Chemical cauterization of cornea was performed on both eyes in 20 rats. Animals were then divided randomly in 5 groups and received, on one eye, a daily subconjunctival injection during 7 consecutive days of one of these 5 treatments: balanced salt solution (BSS); dexamethasone phosphate 0.4mg/day; bevacizumab 2.5mg/day, 3.75mg/day or 5.0mg/day. In all animals, the fellow eye received a subconjunctival injection of BSS. Clinical examination under slit lamp was performed daily for 7 days to evaluate corneal opacity and vessel size evolution. Computer-assisted quantitative image analysis was used to measure the total corneal area covered by neovascularization.

Results: : At final examination, the dexamethasone group showed a significant lowering in corneal opacity score as compared to both control and bevacizumab 2.5mg/day groups (p=0.025; p=0.007). On the new vessels size score, dexamethasone group showed a significant reduction as compared to all other groups (p=0.013). Surface of corneal neovascularization was significantly smaller in dexamethasone and bevacizumab 5.0mg/day groups compared to control (p=0.043 and p=0.049 respectively) and bevacizumab 2.5mg/day groups (p=0 .016 and, p=0 .014 respectively).

Conclusions: : Our study demonstrates the ability of a 5.0mg/day bevacizumab subconjunctival injection to cause a short-term involution of corneal neovascularization after corneal alkali burn but with limited effects compared to steroids. Further studies using combinations of these treatments are needed.

Keywords: vascular endothelial growth factor • corticosteroids • anterior segment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×